Th2 cytokines in focus: proven and new targets

The range of antibody therapies for atopic dermatitis (AD) has expanded once again in Europe. In addition to dupilumab and tralokinumab, lebrikizumab is another biologic available in this country that intervenes specifically in the inflammatory cascade and has an impressive safety profile. Nemolizumab was also recently approved for AD in the EU.